



Curriculum Vitae

Personal information **Hilke Zander**

Work experience

1. Employer: Paul_Ehrlich_Institut
 - Start date: 112013
 - End date:
 - Position: Clinical Assessor
 - Activities: 2017_2021 Observer ONCWP 2018_2021 CTFG_IVD subgroup CDx 2021_present CDx_Expert Group (EMA) since Feb 2023 Alternate SAWP
 - Country: Germany
2. Employer: General, Visceral and Thoracic Surgery Department, University Clinic Hamburg Eppendorf,
 - Start date: 052008
 - End date: 082013
 - Position: Clinical Scientist
 - Activities: biomarker research in oncology, cancer immunotherapy
 - Country: Germany
3. Employer: University College London, Department of Neurology
 - Start date: 012006
 - End date: 052006
 - Position: Technician
 - Activities:
 - Country: United Kingdom
4. Employer: Institut Curie, Department of Cell Biology
 - Start date: 091997
 - End date: 071998
 - Position: Trainee
 - Activities: cancer research
 - Country: France

Education and training

1. Subject: Rheinische Friedrich_Wilhelms_Universität Bonn
 - Start date: 092015
 - End date: 062020
 - Qualification: MSc
 - Organisation: regulatory affairs
 - Country: Germany
2. Subject: Technische Universität München, Institut für Biologische Chemie, Max Planck Institut für Biochemie
 - Start date: 012000
 - End date: 062004
 - Qualification: Dr.rer.nat
 - Organisation: antibody engineering, neuroimmunology, neurodegeneration
 - Country: Germany
3. Subject: Faculty of Medicine, Philipps_University Marburg
 - Start date: 101994
 - End date: 101999
 - Qualification: Dipl._hum.biol.
 - Organisation: theoretical medicine
 - Country: Germany

Additional information

Publications

1. Michaleas S, Moreno Oliver A, Mueller_Berghaus J, Sarac SB, van der Elst ME, Müller_Egert S, Zander H, Enzmann H, Pignatti F. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple_negative breast cancer. ESMO Open. 2022 Jun;7(3):100497 2. Araujo_Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller_Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. The European Medicines Agency review of the initial application of atezolizumab and the role of PD_L1 expression as biomarker for checkpoint inhibitors ESMO Open. 2021 Feb;6(1):100008 3. Trullas A, Delgado J, Genazzani A, Mueller_Berghaus J, Migali C, Müller_Egert S, Zander H, Enzmann H, Pignatti F. The EMA assessment of pembrolizumab as monotherapy for the first_line treatment of adult patients with metastatic microsatellite instability_high or mismatch repair deficient colorectal cancer ESMO Open. 2021 Jun;6(3):100145. 4. Zander H, Müller_Egert S, Zwiewka M, Gross S, van Zandbergen G, Engelbergs J. Checkpointinhibitoren in der Tumorthherapie [Checkpoint inhibitors for cancer therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Nov;63(11):1322_1330. 5. Gebauer F, Gelis S, Zander H, Meyer KF, Wolters_Eisfeld G, Izbicki JR, Bockhorn M, Tachezy M. Tenascin_C serum levels and its prognostic power in nonsmall cell lung cancer. Oncotarget. 2016 Apr 12;7(15):20945_52. 6. Tachezy M, Zander H, Wolters_Eisfeld G, Müller J, Wicklein D, Gebauer F, Izbicki JR, Bockhorn M. Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non_small cell lung cancer? Stem Cells. 2014 Jun;32(6):1429_36. 7. Tachezy M, Zander H, Gebauer F, von Loga K, Pantel K, Izbicki JR, Bockhorn M. CXCR7 expression in esophageal cancer. J Transl Med. 2013 Sep 30;11:238. 8. Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, Bockhorn M. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One. 2012;7(6):e39018. 9. Witzel I, Schroder C, Müller V, Zander H, Tachezy M, Ihnen M, Janicke F, Milde_Langosch K. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology. 2012;82(6):305_12. 10. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR,

Bockhorn M. Activated leukocyte cell adhesion molecule (CD166)its prognostic power for colorectal cancer patients. *J Surg Res.* 2012 Sep;177(1):e15_20 . 11. Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Muller V, Mahner S, Janicke F, Woelber L, Milde_Langosch K. Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. *BMC Cancer.* 2012 Apr 4;12:140. 12. Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, Sauter G, Pantel K, Izbicki JR, Bockhorn M. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. *Int J Cancer.* 2012 Jul 15;131(2):396_405. doi: 10.1002/ijc.26377. Epub 2011 Oct 20. PMID: 21858815. 13. Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients. *J Surg Res.* 2011 Oct;170(2):226_32. 5. 14. Gungor C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, Yekebas E, Bockhorn M. Notch signaling activated by replication stress_induced expression of midkine drives epithelial_mesenchymal transition and chemoresistance in pancreatic cancer. *Cancer Res.* 2011 Jul 15;71(14):5009_19. 15. Zander H, Rawnaq T, von Wedemeyer M, Tachezy M, Kunkel M, Wolters G, Bockhorn M, Schachner M, Izbicki JR, Kaifi J. Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients. *BMC Cancer.* 2011 May 22;11:189:1_7. 16. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. *J Surg Oncol.* 2011 Aug 1;104(2):140_5. 17. Rawnaq T, Quaas A, Zander H, Gros SJ, Reichelt U, Blessmann M, Wilczak W, Schachner M, Sauter G, Izbicki JR, Kaifi JT. L1 is highly expressed in tumors of the nervous system: a study of over 8000 human tissues. *J Surg Res.* 2012 Apr;173(2):314_9. 18. Rawnaq T, Kunkel M, Bachmann K, Simon R, Zander H, Brandl S, Sauter G, Izbicki JR, Kaifi JT. Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. *Ann Surg Oncol.* 2011 Feb;18(2):559_65. 19. Zander H, Reineke U, Schneider_Mergener J, Skerra A. Epitope mapping of the neuronal growth inhibitor Nogo_A for the Nogo receptor and the cognate monoclonal antibody IN_1 by means of the SPOT technique. *J Mol Recognit.* 2007 May_Jun;20(3):185_96. 20. Zander H, Hettich E, Greiff K, Chatwell L, Skerra A. Biochemical characterization of the recombinant human Nogo_A ectodomain. *FEBS J.* 2007 May;274(10):2603_13. . 21. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, Jacob U. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. *Proc Natl Acad Sci U S A.* 2003 Aug 5;100(16):9446_51. 22. Cuif MH, Possmayer F, Zander H, Bordes N, Jollivet F, Couedel_Courteille A,Janoueix_Lerosey I, Langsley G, Bornens M, Goud B. Characterization of GAPCenA, a GTPase activating protein for Rab6, part of which associates with the centrosome. *EMBO J.* 1999 Apr 1;18(7):1772_82.

Projects

Memberships ESMO

Other Relevant Information